Table 4.
Odds ratios of hip fracture associated with ever use of hormone replacement therapy by route of administration and dose
| Use of hormone replacement therapy | Any
|
Without progestin
|
With progestin
|
|||||
|---|---|---|---|---|---|---|---|---|
| No of cases/ controls | Odds ratio* | No of cases/ controls | Odds ratio* | No of cases/ controls | Odds ratio* | |||
| (95% CI) | (95% CI) | (95% CI) | ||||||
| Never used | 956/2073 | 1.0 (reference) | 956/2073 | 1.0 (reference) | 956/2073 | 1.0 (reference) | ||
| All: | ||||||||
| Low dose† | 16/40 | 0.82 (0.45 to 1.51) | 15/29 | 1.02 (0.53 to 1.96) | 1/14 | 0.13 (0.02 to 1.03) | ||
| High dose‡ | 80/347 | 0.55 (0.41 to 0.73) | 46/145 | 0.65 (0.46 to 0.94) | 49/245 | 0.47 (0.33 to 0.69) | ||
| Tablet: | 97/389 | 0.54 (0.41 to 0.71) | 59/173 | 0.63 (0.45 to 0.88) | 55/262 | 0.46 (0.32 to 0.67) | ||
| Low dose† | 14/29 | 0.93 (0.48 to 1.80) | 13/24 | 1.05 (0.52 to 2.12) | 1/7 | 0.21 (0.02 to 1.77) | ||
| High dose‡ | 65/300 | 0.50 (0.36 to 0.68) | 31/98 | 0.61 (0.39 to 0.94) | 49/245 | 0.47 (0.32 to 0.68) | ||
| Skin patch: | 23/94 | 0.62 (0.36 to 1.06) | 15/46 | 0.73 (0.38 to 1.40) | 12/60 | 0.49 (0.24 to 1.00) | ||
| Low dose† | 3/12 | 0.47 (0.12 to 1.85) | 3/6 | 0.84 (0.18 to 3.82) | 0/7 | 0 | ||
| High dose‡ | 14/76 | 0.52 (0.28 to 0.98) | 7/36 | 0.49 (0.21 to 1.17) | 11/51 | 0.56 (0.27 to 1.18) | ||
*
Adjusted for age (50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 81 years) and the indication of hormone replacement therapy to prevent osteoporosis (yes/no).
†
Equivalent to oestradiol <2 mg/day, conjugated oestrogens <0.625 mg/day, ethinyl oestradiol <10 μg/day, transdermal oestradiol <50 μg/day, or any oestradiol given by injection.
‡
Equivalent to oestradiol ⩾2 mg/day, conjugated oestrogens ⩾0.625 mg/day, ethinyl oestradiol ⩾10 μg/day, transdermal oestradiol ⩾50 μg /day, or any oestradiol given by injection.